Literature DB >> 21436849

The prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom.

L-Y Ngai1, N Stocks, J M Sparrow, R Patel, A Rumley, G Lowe, G Davey Smith, Y Ben-Shlomo.   

Abstract

AIMS/
PURPOSE: To determine the prevalence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) in men aged 65-83 years living in the Speedwell region of Bristol, United Kingdom and identify modifiable risk factors.
METHODS: A total of 2348 men recruited to the Speedwell prospective cohort study in 1979 were followed up in 1997 with an eye questionnaire and had retinal photographs that were assessed using the International Classification System for ARM.
RESULTS: In all, 934 men (66.8% response rate) attended with a mean of 17.9 years (15.3-20.6 years) follow-up. Early ARM (grades 2-3) was found in 9.2% (95% confidence interval (CI) 7.4%, 11.4%) and late age-related maculopathy (grade 4, AMD) in 0.5% (95% CI 0.2%, 1.2%). The risk of ARM (grades 2-4) was increased with raised C-reactive protein and consumption of lard and solid fats, whereas triglyceride levels were associated with a lower risk. The latter were confirmed in multivariable analyses and in addition, haemodynamic measures also predicted risk (eg mean arterial pressure odds ratio (OR) per z-score 1.37, 95% CI 1.04, 1.79).
CONCLUSIONS: In a representative cohort of men aged 65-83 from Bristol, United Kingdom, many had macular changes that put them at higher risk of developing AMD. Various modifiable exposures were associated with an increased risk ARM/AMD. Opportunities for screening and undertaking secondary prevention interventions need to be explored to prevent progression of the disease and blindness.

Entities:  

Mesh:

Year:  2011        PMID: 21436849      PMCID: PMC3178119          DOI: 10.1038/eye.2011.56

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  81 in total

Review 1.  The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration.

Authors:  E Friedman
Journal:  Am J Ophthalmol       Date:  2000-11       Impact factor: 5.258

2.  Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study.

Authors:  C Delcourt; F Michel; A Colvez; A Lacroux; M Delage; M H Vernet
Journal:  Ophthalmic Epidemiol       Date:  2001-09       Impact factor: 1.648

3.  Risk factors for age-related maculopathy: the Visual Impairment Project.

Authors:  C A McCarty; B N Mukesh; C L Fu; P Mitchell; J J Wang; H R Taylor
Journal:  Arch Ophthalmol       Date:  2001-10

4.  Drusen proteome analysis: an approach to the etiology of age-related macular degeneration.

Authors:  John W Crabb; Masaru Miyagi; Xiaorong Gu; Karen Shadrach; Karen A West; Hirokazu Sakaguchi; Motohiro Kamei; Azeem Hasan; Lin Yan; Mary E Rayborn; Robert G Salomon; Joe G Hollyfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

5.  Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project.

Authors:  M R VanNewkirk; L Weih; C A McCarty; H R Taylor
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

6.  Prospective study of dietary fat and the risk of age-related macular degeneration.

Authors:  E Cho; S Hung; W C Willett; D Spiegelman; E B Rimm; J M Seddon; G A Colditz; S E Hankinson
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

7.  Prevalence of cataract in the Speedwell Cardiovascular Study: a cross-sectional survey of men aged 65-83.

Authors:  N Stocks; R Patel; J Sparrow; G Davey-Smith
Journal:  Eye (Lond)       Date:  2002-05       Impact factor: 3.775

8.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study.

Authors:  C C Klaver; J J Assink; R van Leeuwen; R C Wolfs; J R Vingerling; T Stijnen; A Hofman; P T de Jong
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

Review 9.  A role for local inflammation in the formation of drusen in the aging eye.

Authors:  Don H Anderson; Robert F Mullins; Gregory S Hageman; Lincoln V Johnson
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

10.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Stacy M Meuer; Guan-Hua Huang
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

View more
  11 in total

1.  Improving care and increasing efficiency-challenges in the care of chronic eye diseases.

Authors:  A Kotecha; S Turner; C Vasilakis; M Utley; N Fulop; A Azuara-Blanco; P J Foster
Journal:  Eye (Lond)       Date:  2014-07       Impact factor: 3.775

2.  Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study.

Authors:  C Wilde; A Poostchi; R L Mehta; H K MacNab; J G Hillman; S A Vernon; W M Amoaku
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

3.  The Association between the Lipids Levels in Blood and Risk of Age-Related Macular Degeneration.

Authors:  Yafeng Wang; Mingxu Wang; Xiaoqing Zhang; Qianyu Zhang; Jing Nie; Ming Zhang; Xiaohong Liu; Le Ma
Journal:  Nutrients       Date:  2016-10-22       Impact factor: 5.717

4.  Ophthalmologic evaluation of severely obese patients undergoing bariatric surgery: A pilot, monocentric, prospective, open-label study.

Authors:  Chiara Posarelli; Guido Salvetti; Paolo Piaggi; Francesca Guido; Giovanni Ceccarini; Ferruccio Santini; Michele Figus
Journal:  PLoS One       Date:  2019-05-16       Impact factor: 3.240

Review 5.  Risk factors for progression of age-related macular degeneration.

Authors:  Thomas J Heesterbeek; Laura Lorés-Motta; Carel B Hoyng; Yara T E Lechanteur; Anneke I den Hollander
Journal:  Ophthalmic Physiol Opt       Date:  2020-02-25       Impact factor: 3.117

Review 6.  Not All Stressors Are Equal: Mechanism of Stressors on RPE Cell Degeneration.

Authors:  Yao Tong; Shusheng Wang
Journal:  Front Cell Dev Biol       Date:  2020-11-19

7.  Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients.

Authors:  Abdullah Ozkaya; Zeynep Alkin; Yalcin Karakucuk; Dilek Yasa; Ahmet Taylan Yazici; Ahmet Demirok
Journal:  ISRN Ophthalmol       Date:  2013-08-29

8.  Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?

Authors:  Abdullah Ozkaya; Zeynep Alkin; Hande Mefkure Ozkaya; Alper Agca; Engin Bilge Ozgurhan; Yalcin Karakucuk; Ahmet Taylan Yazici; Ahmet Demirok
Journal:  J Ophthalmol       Date:  2013-11-11       Impact factor: 1.909

9.  The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.

Authors:  Ozlem Dikmetas; Sibel Kadayıfcılar; Bora Eldem
Journal:  Mol Vis       Date:  2013-12-20       Impact factor: 2.367

10.  Experiences with developing and implementing a virtual clinic for glaucoma care in an NHS setting.

Authors:  Aachal Kotecha; Alex Baldwin; John Brookes; Paul J Foster
Journal:  Clin Ophthalmol       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.